Syndax Pharmaceuticals director sells 8,000 shares

Q: How many SNDX shares did Dennis Podlesak sell, and at what price?

Dennis Podlesak sold 8,000 shares on October 29, 2026, at a reported price of $14.2145 per share; sale prices ranged from $14.00 to $14.59. The sales were made under a Rule 10b5-1 plan.

Q: What happened to Dennis Podlesak's SNDX options?

Podlesak exercised options for 8,000 common shares at an $11.81 exercise price. After the sales, he had 127,000 vested and immediately exercisable options and no unvested options.

The Rule 10b5-1 plan applied only to equity grants expiring before October 31, 2026, while 127,000 vested options remained immediately exercisable after the sale.

Available on EDGAR 10/30/2026 - 07:10 PM EDT Accepted by SEC EDGAR 10/30/2026 - 07:09 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Syndax Pharmaceuticals Inc director Dennis Podlesak exercised options for 8,000 common shares on October 29, 2026, at an $11.81 exercise price, then sold 8,000 shares at a reported $14.2145 per share; sale prices ranged from $14.00 to $14.59. The sales were made under a Rule 10b5-1 plan adopted by Podlesak, covering only equity grants expiring before October 31, 2026. After the sales, he had 127,000 options that were vested and immediately exercisable, and no unvested options.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,000 shares ($19K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Podlesak Dennis

Role Director

Sold 8,000 shs ($114K)

Approx. gross sale proceeds $114K

Approx. exercise cost $94K

Approx. pre-tax spread $19K

Share of Position Sold 3.2%

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to buy) ^F3	8,000	$0.00	$0.00
Exercise	Common Stock	8,000	$11.81	$94K
Sale	Common Stock ^{F1, F2}	8,000	$14.2145	$114K

Holdings After Transaction: Stock Options (Right to buy) — 0 contracts (Direct); Common Stock — 239,763 shares (Direct)

Holdings Before and After: Stock Options (Right to buy), 8,000 to 0 contracts (Direct); Common Stock, 239,763 to 239,763 shares (Direct)

Footnotes (3)

F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to Octobre 31, 2026. Following the sales reported in this Form 4, the Reporting Person has a total of 127,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
F2. The sale prices ranged from $14.00 to $14.59.
F3. This option is fully vested.

Key Figures

Shares sold: 8,000 shares Shares acquired through option exercise: 8,000 shares Exercise price: $11.81 per share +3 more

6 metrics

Shares sold 8,000 shares October 29, 2026

Shares acquired through option exercise 8,000 shares October 29, 2026

Exercise price $11.81 per share Options exercised October 29, 2026

Reported sale price $14.2145 per share Sale on October 29, 2026

Sale price range $14.00 to $14.59 per share Sales reported on October 29, 2026

Remaining vested, immediately exercisable options 127,000 options After the sales

Key Terms

Rule 10b5-1 plan, fully vested, immediately exercisable

3 terms

Rule 10b5-1 plan regulatory

"effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

fully vested technical

"This option is fully vested."

immediately exercisable financial

"vested and immediately exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SNDX shares did Dennis Podlesak sell, and at what price?

Dennis Podlesak sold 8,000 shares on October 29, 2026, at a reported price of $14.2145 per share; sale prices ranged from $14.00 to $14.59. The sales were made under a Rule 10b5-1 plan.

What happened to Dennis Podlesak's SNDX options?

Podlesak exercised options for 8,000 common shares at an $11.81 exercise price. After the sales, he had 127,000 vested and immediately exercisable options and no unvested options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Podlesak Dennis

(Last)

(First)

(Middle)

C/O SYNDAX PHARMACEUTICALS, INC.

730 THIRD AVENUE, FLOOR 9

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026		M		8,000	A	$11.81	247,763	D
Common Stock	10/29/2026		S⁽¹⁾		8,000	D	$14.2145⁽²⁾	239,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to buy)	$11.81	10/29/2026		M			8,000	⁽³⁾	10/31/2026	Common Stock	8,000	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to Octobre 31, 2026. Following the sales reported in this Form 4, the Reporting Person has a total of 127,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.

2. The sale prices ranged from $14.00 to $14.59.

3. This option is fully vested.

	/s/ Michael A. Metzger, Attorney-in-Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR